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emic subjects reported that high levels of total IgG was associated
with a higher incidence of CHD (Kovanen et al., 1998). It is of course
possible that total Ig is a marker higher risk in subjects with dyslipid-
emia and a marker of lower risk in subjects with hypertension but it is
difﬁcult to see a pathophysiological rational for this. Hence, more stud-
ies are needed before the clinical value of total Ig measurements in car-Antibodies represent one the most effective tools to ﬁght invading
pathogens used by the immune system. By binding to speciﬁc epitopes
on virus and bacteria they can neutralize toxins, activate complement
and enhance phagocytic clearance. Some antibodies also bind self-anti-
gens helping to clear away apoptotic cells and other debris providing
important house-keeping functions. However, the generation of these
protective autoantibodies presents a considerable challenge to the im-
mune system because expression of antibodies that react with the
wrong self-antigens may cause autoimmune disease. The possible role
of antibodies in cardiovascular disease has attracted considerable atten-
tion and evidence for both protective and pathogenic roles has been ob-
tained (Tsiantoulas et al., 2014). In the present issue of EBioMedicine,
Khamis and co-workers report that subjects that go on to suffer from
coronary heart disease (CHD, including myocardial infarction, death
from coronary heart disease and coronary revascularization) are charac-
terized not only traditional risk factors such as smoking, hypertension
and hypercholesterolemia but also by lower levels of total IgG and to
some extent also lower levels of IgM (Khamis et al., 2016). Remarkably,
thosewith IgG in the highest tertile had an almost 60% lower risk of CHD
than those in the lowest IgG tertile. The association between low IgG
levels and CHD remained when controlling for the variables used in
the Framingham risk score and inclusion of IgG improved risk predic-
tion and decreased misclassiﬁcation into low and high risk individuals.
The ﬁndings could potentially be of considerable clinical importance
and raise two interesting questions. First, should analyses of total plas-
ma Ig be used clinically as a biomarker to improve prediction of cardio-
vascular risk? This is an attractive possibility because the assay for total
Ig is simple, robust and relatively cheap. However, as pointed out by the
authors these ﬁndings ﬁrst need to be conﬁrmed in other and larger co-om.2016.06.012.
. This is an open access article underhorts. This is particularly important since a previous study on dyslipid-
diovascular risk prediction can be truly assessed. The second and much
more complex question is whether a low level of total Ig is a cardiovas-
cular risk factor, e.g. Do Ig have a protective function in the cardiovascu-
lar system? The possible role of B cells in atherosclerosis has been
extensively studied in experimental models but with inconsistent re-
sults (Tsiantoulas et al., 2014). Most evidence suggests that B1 cells,
which produce germline-encoded natural IgM binding to phospholipid
epitopes onmicroorganisms and apoptotic cells, have a protective effect
(Binder et al., 2005). This notion is also supported by ﬁndings of acceler-
ated atherosclerosis inmice deﬁcient for IgM (Lewis et al., 2009) and re-
duced atherosclerosis following treatment with natural antibodies
(Faria-Neto et al., 2006). In contrast, most experimental evidence sup-
port a pro-atherogenic role of B2 cells but it remains to be fully under-
stood whether this effect is dependent of IgG secretion or a cross-talk
with pro-atherogenic Th1 cells (Tsiantoulas et al., 2014). Treatment
with high doses of polyclonal IgG reduces atherosclerosis in mice
(Nicoletti et al., 1998) but it is questionable if IgG at the concentrations
normally found in humans can have this effect. There are also reports of
athero-protective effects of speciﬁc IgG in mouse models of atheroscle-
rosis (Schiopu et al., 2007). These IgGwere generated against certain al-
dehyde-modiﬁed peptide sequences in apolipoprotein B-100 and
reduce inﬂammation through binding to the inhibitory Fc-gamma re-
ceptor IIB (Li et al., 2013). However, treatment with these antibodies
failed to reduce carotid plaque inﬂammation in patients with stable car-
diovascular disease in a randomized clinical trial (Lehrer-Graiwer et al.,
2015). It remains to be clariﬁed whether the negative outcome of this
study was due to a lack of athero-protective effects of the antibody in
humans or if the level of plaque inﬂammation in these stable patients
was too low for the antibody to have a detectable effect. Notably,
Khamis and co-workers found a stronger association between total
IgG and CHD than between IgG against aldehyde-modiﬁed LDL and
CHD. Since IgG against aldehyde-modiﬁed LDL only represent one sub-
class of anti-oxidized LDL antibodies this does not exclude that other
types of oxidized LDL antibodies may explain the association between
total IgG and cardiovascular risk. However, it is also possible that thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
30 J. Nilsson / EBioMedicine 9 (2016) 29–30latter association is dependent on entirely differentmechanisms such as
an improved protection against infections.
The ﬁndings reported by Khamis and co-workers will stimulate
others to further explore the possible role of antibodies in cardiovascu-
lar disease. If addingmeasurements of total IgG can be conﬁrmed to im-
prove cardiovascular risk prediction by currently used scores this would
represent a signiﬁcant clinical breakthrough. It would also strengthen
the case for the immune system as a novel target for prevention and
treatment of cardiovascular disease.
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